Navigation Links
GORE DUALMESH® Biomaterial

ProductsGORE DUALMESH® Biomaterial
Company W. L. Gore & Associates, Inc.
Item GORE DUALMESH® Biomaterial
Features 
  • Soft, conformable
  • Constructed of ePTFE sheet material
  • Offers a unique, dual-surface design
  • Features two functionally distinct surfaces: a closed structure surface for reduced tissue attachment and a macroporous
  • structure surface for faster tissue attachment
    • Description In certain hernia and soft tissue reconstructions, and in temporary bridging of fascial defects, it is sometimes necessary to encourage host tissue ingrowth along one surface, while minimizing tissue attachment along another surface. GORE DUALMESH® Biomaterial is a soft, conformable, ePTFE sheet material that offers a unique, dual-surface design intended for such applications. The biomaterial features two functionally distinct surfaces: a closed structure surface for reduced tissue attachment and a macroporous structure surface for faster tissue attachment.
    Info W. L. Gore & Associates, Inc.
    Customer Service: (800) 437-8181
    Web site: http://www.goremedical.com/

    Related medicine products :

    1. GORE MYCROMESH® PLUS Biomaterial
    2. GORE MYCROMESH Biomaterial
    3. GORE DUALMESH PLUS Biomaterial
    ... advance of digital imaging technology, pathology ...formats, allowing for easier manipulation, analysi...in digital pathology imaging is analogous to the c...tinuing to occur in hospital imaging departments a...
    The CellTracks® Analyzer II is a semi-automated fluorescence microscope used to enumerate fluorescently labeled cells that are immunomagnetically selected and aligned. The product consists of the
    These Iron Control Slides make an excellent addition to your laboratory. Packed ten (10) control slides per box. Use SDL's Snap n' Stain for Iron Staining Kit alongside to save time an money mixing r
    PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques.
    Medicine Products:
    (Date:7/9/2008)...tes In-Store and Online Marketing to Create Unique...TTSBURGH and NEW YORK, July 9 /PRNewswire-FirstCal...largest global specialty retailer of,nutritional p...ource of,health information, today announced a mul... awareness and understanding of the importance of ...
    (Date:7/9/2008)...y 9 /PRNewswire-FirstCall/ -- Nyer Medical Group,...DCO South Medical Supplies,Inc., ("ADCO South") i...,announced that its pharmacy division, D.A.W. Inc....ior Living, Inc. to be the preferred pharmacy,prov...cilities in,Massachusetts. The award was made at t...
    (Date:7/9/2008)...RNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE:,M...o the global life,sciences markets, today announce...ed (AECL) with notice of arbitration proceedings. ...fill its contractual obligations,under its 2006 in...f not,granted, seeking significant monetary damage...
    (Date:7/9/2008)... Radiotherapy Clinics of Georgia (RCOG) has beg...ing campaign. RCOG is renowned for their ProstRcis...st documented prostate cancer cure rates in the wo...B) July 9, 2008 -- Radiotherapy Clinics of Georgia...r click campaign that incorporates geo targeting f...
    Breaking Medicine News(10 mins):Health News:GNC and WebMD Announce Agreement To Provide Consumers with Health and Nutritional Information While Promoting the Benefits of a Healthy Lifestyle 2Health News:GNC and WebMD Announce Agreement To Provide Consumers with Health and Nutritional Information While Promoting the Benefits of a Healthy Lifestyle 3Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 2Health News:Nyer Medical Group, Inc. Announces Sale of Company's Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract 3Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 3Health News:Localized Online Marketing Campaign Serves to Raise Awareness of Prostate Cancer Treatment 2Health News:Localized Online Marketing Campaign Serves to Raise Awareness of Prostate Cancer Treatment 3
    ...ue to changes in the tissue environment of the bre...er by McDaniel. This study has found a place in th...ogy. // The stages of pregnancy, lactation, and i... the tissues of the human breast, resulting in mul...
    ...improper usage of MP3 and iPods, like listening to...ecting the hearing capabilities of a person. // Th...aul R. Kileny revealed that such devices are not i...if not used in the proper manner. Most people find...
    ...e unlucky for Biomedical Tissue Services Ltd a com...on from cadavers. // The Food and Drug Administr...aws in the donor policies that might pose a threat... to disease. Though, none of the patients have bee...
    ...n University have revealed that the ageing of the ...ls. // This conclusion has been arrived at after s...in it was found that as the animals grow older, th... the ageing cells in their skin. The idea that c...
    Other Medicine News:Health News:Chicago :FDA imposes Ban on Biomedical Tissue Services 2
    (Date:7/7/2008)...e/ -- OrbusNeich today announced that data,present...nese Society of,Interventional Cardiology demonstr...ter outcomes when compared to drug-eluting stents....,s principal,investigator and a professor with the...rdiology, Department of Clinical Medicine and Card...
    (Date:7/7/2008)...fruit is Top Performer in the Body, SEATTLE, July...l when,it comes to their antioxidant powers in the...bility compared to other antioxidant-rich fruits a... in the Journal of the,American College of Nutriti...cals called flavonoids that,may have the power to ...
    (Date:7/3/2008)...swire-FirstCall/ -- Medivation, Inc.,(Nasdaq: MDV...ence at 5:00,p.m. EDT on Monday, July 7, to discus...nd, placebo-controlled Phase 2 clinical trial of,d...ce/Webcast Details, To participate in the live ca... telephone, please dial 877-419-6590 from the U.S....
    (Date:7/3/2008)...BRIDGE Massachusetts, July 3,/PRNewswire-FirstCall...logy company, Jerini AG for an equity purchase pr... (HAE) product, FIRAZYR(R), to its Human Genetic ...global sales expected to be around $350-400 milli...e environment, - Expected to be accretive for Non...
    Breaking Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Kiwifruit: Antioxidant Power in Quantity and Quality 2Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 4Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 6Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 7Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 8Complementary Excerpt Available from Best Practices 3A Resources Structure and Processes to Optimize Pharmaceutical Sales Communications 17241 1Complementary Excerpt Available from Best Practices 3A Resources Structure and Processes to Optimize Pharmaceutical Sales Communications 17241 2Gene Therapy in Rats Reduces Cocaine Use 17237 1Gene Therapy in Rats Reduces Cocaine Use 17237 2Dealing Cervical Cancer a Knockout Blow 17234 1Dealing Cervical Cancer a Knockout Blow 17234 2Dealing Cervical Cancer a Knockout Blow 17234 3Best Practice Database 3A Valuable Strategies for Pharmaceutical Product Launches 17230 1Best Practice Database 3A Valuable Strategies for Pharmaceutical Product Launches 17230 2
    ...HICAGO, June 21, 2007 /PRNewswire-FirstCall/ -- Ad...ced positive results from,Trial CL-06, the first o...assess the safety and effectiveness of cethromycin... of community,acquired pneumonia (CAP). In the stu...imary endpoint of per protocol clinical,cure rate ...
    ...ummary: Pharmexa-Epimmune, the U.S.-based subsidia...s influenza vaccine,program today at the Influenza...Influenza VI," held in Toronto, Ontario, Canada. T...o induce,cell-mediated immune responses can protec...uenza virus challenge. , HORSOLM, Denmark, June 21...
    Other Medicine Technology:Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 2Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 3Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 4Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial 5Pharmexa A/S (DK) - Pharmexa presents data from influenza program 2